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OBJECTIVES The study was done to investigate the relationship between clinical restenosis and the relative
angiographic location of the recurrent restenotic lesion, after treatment of in-stent restenosis
with vascular brachytherapy in the Washington Radiation for In-Stent Restenosis Trial
(WRIST).
BACKGROUND Intracoronary radiation therapy reduces recurrence of in-stent restenosis. We investigated the
above objective in patients enrolled in WRIST.
METHODS The WRIST study randomized 130 patients to double-blinded therapy with gamma
irradiation (iridium-192 [192Ir]) versus placebo after interventional treatment of diffuse
in-stent restenosis. After the intervention and at follow-up, three vessel segments were
individually analyzed with quantitative coronary angiography: 1) the “stent,” 2) the “radiation
ribbon,” and 3) the “ribbonmargin” segment (including 5 mm on either end of the injured
or radiation-ribbon segment). Receiver operator curves (ROC) were used to assess the value
of the follow-up percent diameter stenosis (DS) for each of the three analyzed segments in
predicting target vessel revascularization (TVR).
RESULTS 192Ir reduced recurrent restenosis (23.7% vs. 60.7%, p  0.001) and the length of recurrent
restenosis (8.99  4.34 mm vs. 17.54  10.48 mm, p  0.001) at follow-up compared to
placebo. Isolated stent edge (3.4%) and ribbon edge (1.7%) restenoses were infrequent in both
groups. The best angiographic surrogate of TVR was the 50% follow-up DS obtained from
the ribbonmargin analysis (ROC area 0.806).
CONCLUSIONS In WRIST, not only was 192Ir therapy effective in reducing restenosis, but it also reduced the
lesion length of treatment failures by 50%, and it was not associated with edge proliferation.
The restenosis rate obtained from the vessel segment inclusive of the dose fall-off zones was
the best correlate of TVR and should become a standard analysis site in all vascular
brachytherapy trials. (J Am Coll Cardiol 2002;39:274–80) © 2002 by the American
College of Cardiology
The angiographic evaluation of brachytherapy trials has
become more challenging due to the extended length of the
segments receiving therapy, the multiple associated land-
marks (lesion, balloon injury, stent, and radiation delivery),
and the fact that recurrent stenosis may theoretically occur
at any location spanning the stent, the radiation delivery
catheter, or its dose fall-off edges. A better understanding of
the luminal changes that occur after vascular brachytherapy
is necessary to optimize radiation prescription and delivery
techniques. To that end, we reviewed the quantitative
angiographic methods and results of the Washington Ra-
diation for In-Stent Restenosis Trial (WRIST) (1). The
specific aims of this angiographic substudy were: 1) to define
the segment landmarks used in the angiographic analysis, 2)
to determine the location, pattern and predictors of treat-
ment failures, and 3) to determine the best angiographic
correlate of clinical revascularization in patients undergoing
vascular brachytherapy.
METHODS
Patient population and procedure. Between March 1997
and December 1998, a total of 130 consecutive patients with
native vessel (n  100) or saphenous vein graft (n  30)
stent restenosis were assigned to treatment with iridium-
192 (192Ir) or to placebo in the WRIST study. Patients were
included in this study if they had a single in-stent restenotic
lesion up to 47 mm in length in a 3.0- to 5.0-mm vessel.
The procedural details of WRIST have been published in
detail elsewhere (1). After successful intervention, patients
were randomly assigned to treatment with either 192Ir or
placebo. Discrete lesions were treated with a 19- or 23-mm-
long ribbon containing five or seven 3-mm sources; longer
lesions were treated with a 35-mm, 51-mm, or 55-mm
ribbon containing nine, thirteen, or fifteen 3-mm seeds
(Best Medical International, Springfield, Virginia). The
ribbons were precisely positioned to span the treated lesion.
The mean dwell time was 21.7 min, sufficient to deliver 15
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Gy to a target site 2 mm from the source surface for 3.0- to
4.0-mm vessels, and 24 Gy for 4.0-mm vessels. After
removal of the ribbon, cineangiography was repeated to
document the absence of complications. Follow-up was
obtained at six months.
Angiographic analysis. All procedural and follow-up
cineangiograms were analyzed independently by observers
who were blinded to the treatment strategy. Standard
morphologic criteria were used to characterize baseline
lesion complexity (2) and identify the occurrence of angio-
graphic complications (3). Lesion length was determined by
the “shoulder-to-shoulder” extent of obstruction both at
baseline and at follow-up.
Quantitative coronary angiography (QCA) was performed
sequentially at baseline, after intervention and at follow-up,
using the CMS-GFT algorithm (MEDIS, Leiden, The Neth-
erlands) guided by the analyst’s drawing of the arterial segment
and its side branches, demonstrating the precise location of the
baseline stenosis, the stent, and the radiation delivery ribbon
(Fig. 1) (4). The minimal lumen diameter (MLD) and the
mean reference diameter (RD), obtained from averaging a
5-mm segment proximal and distal to the final ribbon or
injuredmargin location, were used for calculations of %DS
[diameter stenosis]  [(1  MLD/RD)  100].
Abbreviations and Acronyms
DS  diameter stenosis
192Ir  iridium-192
MLD  minimal lumen diameter
RD  reference diameter
ROC  receiver operator curve
TVR  target vessel revascularization
WRIST  Washington Radiation for In-Stent
Restenosis Trial
Figure 1. Schematic representation of the stent, ribbon, and ribbonmargin segment analysis. A (arrows) represented the axial length of the stent analysis
after the procedure; B (arrows) represented the ribbon analysis; C (arrows) represented the ribbonmargin analysis including approximately 5 mm of
margins beyond the ribbon (includes any injury). The three analyses at follow-up enabled definition of (a) restenosis at the margin of the stent within the
radiated segment [(ribbon restenosis)  (stent restenosis)], (b) restenosis at the margin of the radiation ribbon [(ribbon  margin restenosis)  (ribbon
restenosis)], and (c) restenosis beyond the stent margin [(ribbon margin restenosis) (stent restenosis)]. Five-millimeter segments of proximal and distal
reference diameters are averaged to estimate the reference vessel diameter.
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After final treatment and at follow-up, three separate
analyses were performed: 1) a “stent” analysis, which iden-
tified the MLD within the axial stent length; 2) a “ribbon”
analysis, which identified the MLD within the segment
spanning the radiation delivery ribbon; and 3) a
“ribbonmargin” analysis, which identified the MLD in the
segment spanning the ribbon and including a 5-mm margin
proximal and distal to the ribbon or injured zone (Fig. 1).
An MLD of 0.0 was imputed in the presence of a total
occlusion at baseline or at follow-up. Acute gain was defined
as the change in the MLD from baseline to the final
procedural angiogram; late loss was defined as the change in
MLD from the final to the follow-up angiogram. The
arithmetic loss index was defined as (late loss)/(acute gain).
Binary restenosis was defined as a 50% DS at follow-up.
The three analyses at follow-up enabled definition of (a)
restenosis at the margin of the stent within the radiated
segment [(ribbon restenosis)  (stent restenosis)], (b) re-
stenosis at the margin of the radiation ribbon [(ribbon 
margin restenosis)  (ribbon restenosis)], and (c) restenosis
beyond the stent margin [(ribbon  margin restenosis)
[(ribbon  margin restenosis)  (stent restenosis)] (Fig. 1).
Statistical analysis. Continuous variables are presented as
mean  SD; ordinal variables are presented as frequencies.
Comparison between continuous variables was performed
using the Student t test; comparisons between ordinal
variables were performed using chi-square or the Fisher
exact test, when indicated. A p  0.05 was considered
significant. Paired statistical tests were used for comparing
different analysis segments within each treatment group.
Paired t tests were used for continuous variables, and the
McNemar test was used for categorical variables. The
Bonferroni adjustment was used to control for multiple
comparisons. Receiver operator curves (ROC) were used to
assess the value of the follow-up percent DS obtained using
the three different segments analyzed (stent, ribbon, and
ribbonmargin) in predicting clinically driven target vessel
revascularization (TVR). Multivariable logistic regression
analyses were performed to identify clinical and angio-
graphic predictors of restenosis in all patients enrolled in
WRIST and those patients randomized to radiation ther-
apy. Binary stepwise multivariate logistic regression analysis
utilized p values of 0.10 for entry and 0.20 for removal. A
two-tailed p value  0.05 was considered significant.
RESULTS
Lesion characteristics. Baseline and follow-up angiograms
technically suitable for quantitative angiographic analysis
were available in 128 and in 117 of 130 patients, respec-
tively. Treated lesion location and baseline complexity were
similar in the 192Ir and placebo groups (1). Patients with
American College of Cardiology/American Heart Associa-
tion (ACC/AHA) B2 and C lesion complexity (63%), and
mean lesion length (20.5  10.5 mm), were similarly
distributed in the two groups. The mean seed to lesion
length ratio was 1.82  0.87. After the final procedure,
dissections remained in 18.8% of 192Ir and 12.5% of placebo
patients (p  0.33). No late angiographic complications
related to radiation treatment, such as the development of
aneuryms or arterial constriction, were observed. All dissec-
tions remaining at the final procedure were healed at follow-
up. The follow-up lesion length was significantly longer in
placebo compared to 192Ir-treated patients (17.54 10.48 mm
vs. 8.99  4.34 mm; p  0.0001).
Quantitative angiographic results. Quantitative angio-
graphic findings are in Tables 1 and 2. Reference vessel
diameters and the postprocedure stent, ribbon or
ribbonmargin MLDs were similar for both 192Ir and
placebo-treated patients. At follow-up the stent, ribbon and
ribbonmargin MLD values were significantly larger in
192Ir-treated patients (p 0.001 for all). The distribution of
follow-up MLDs for the stent analysis demonstrated a near
bimodal distribution with systematically larger MLDs with
iridium therapy. For the ribbonmargin analysis, the dis-
tribution of follow-up MLDs, although demonstrating
more overlap, still had systematically larger MLDs with
192Ir therapy compared to placebo (Fig. 2).
The 192Ir-treated patients had a lower late loss and loss
index compared to placebo-treated patients regardless of the
vessel segment analyzed (p  0.001) (Table 2). Unlike
placebo patients, 192Ir patients had a significantly lower late
loss within the stent than within the ribbon or the
ribbonmargin (p  0.001 for both comparisons); accord-
Table 1. Quantitative Angiographic Results
192Iridium Placebo
p
Value
No. of patients 64 64
Reference (mm)
Baseline 2.71  0.53 2.72  0.56 0.908
Final 2.79  0.50 2.85  0.50 0.544
Follow-up 2.90  0.52 2.87  0.58 0.788
MLD (mm)
Baseline 0.94  0.42 0.81  0.42 0.074
Final
Stent 2.23  0.52* 2.25  0.50* 0.851
Ribbon 2.00  0.68 2.10  0.51 0.336
Lesion (ribbonmargin) 2.00  0.47 2.05  0.42 0.514
Follow-up
Stent 2.01  0.93* 1.24  0.77† 0.0001
Ribbon 1.72  0.95 1.14  0.86 0.0008
Lesion (ribbonmargin) 1.70  0.78 1.20  0.75 0.0007
% Stenosis
Baseline 65.2  14.3 70.4  14.6 0.0471
Final
Stent 19.8  15.2* 20.5  14.8* 0.799
Ribbon 28.4  22.9 26.2  12.0 0.5120
Lesion (ribbonmargin) 28.3  11.9 27.3  12.0 0.631
Follow-up
Stent 30.1  30.0* 57.9  22.0† 0.0001
Ribbon 41.5  30.5 60.7  24.6 0.0003
Lesion (ribbonmargin) 42.1  23.3 59.3  20.1 0.0001
A single culprit lesion is reported for each patient.
*p  0.001 for comparison of stent versus ribbon and stent versus ribbonmargin;
†p  0.05 for comparison of stent versus ribbon and stent versus ribbonmargin.
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ingly, the loss index within the stent was lower than within
the ribbonmargin segment (p  0.0223).
Edge restenosis after gamma radiation. Compared with
placebo patients, 192Ir-treated patients had lower stent
restenosis rates (p  0.001), ribbon restenosis (p  0.001)
and ribbonmargin segment restenosis rates (p  0.001).
Isolated stent margin restenosis occurred in only 3.4% of
lesions, and isolated ribbon margin restenosis occurred in
1.7% of treated lesions. There was no significant increase or
reduction in the restenosis rate with 192Ir therapy at the
stent margin (3.4% radiation vs. 3.4% placebo; p  0.5) or
at the ribbon margin only (1.7% radiation vs. 1.7% placebo,
p  0.6). Ribbon or stent edge restenosis was unrelated to
the extent of coverage of the stent edges with seeds. A total
of four patients in the iridium group had inadequate
coverage of both the proximal (mean of two seeds) and the
distal edge (mean of three seeds) of the stent with active
seeds. Restenosis did not occur in any of these patients. In
the two patients with stent edge restenosis including the
patient with restenosis at the edge of the radiation delivery
catheter, there was extensive coverage of the proximal and
distal edge areas by 6 and 10 seeds, respectively.
Predictors of recurrent angiographic restenosis. In the
overall WRIST population, univariate predictors of reste-
nosis included 192Ir therapy, lesion length, baseline MLD,
lesion complexity, final ribbon MLD, and reference diam-
eter, but only three factors were independently predictive of
restenosis: 1) 192Ir therapy (OR [odds ratio] 0.175, 95% CI
[confidence interval] 0.064–0.476, p  0.0006); 2) increas-
ing lesion length (per mm) (OR 1.073, 95% CI [1.017–
1.133], p  0.01); and 3) increasing reference vessel size
(per mm) (OR 0.339, 95% CI [0.115–0.995], p  0.049).
Among patients who received 192Ir therapy only, univariate
predictors included lesion length, RD, final ribbon MLD,
ostial location, and left anterior descending coronary artery
(LAD) location, but only increasing lesion length (per mm)
(OR 1.133, 95% CI [1.032–1.245], p  0.0091), ostial
location (OR 16.32, 95% CI [1.94–137.32], p  0.01020)
and LAD location (OR 12.37, 95% CI [1.76–86.92], p 
0.0115) were significant independent predictors of resteno-
sis by multivariate analysis.
Figure 3 describes the relationship between initial lesion
length and the probability of restenosis within the in-stent
segment, the stent edge segment and the entire treated
(ribbonmargins) segment. It is evident that the relation-
ship between these two parameters is different at the stent
Table 2. Serial Changes in Lumen Dimensions
192Iridium Placebo p Value
Acute gain (mm)
Stent 1.29 0.53† 1.44 0.53† 0.1072
Ribbon 1.06 1.75 1.29 0.50 0.0396
Lesion (ribbonmargin) 1.06 0.50 1.25 0.48 0.0334
Late loss (mm)
Stent 0.24 0.84 1.00 0.69† 0.0001
Ribbon 0.28 0.73 0.88 0.64 0.0001
Lesion (ribbonmargin) 0.32 0.70 0.84 0.70 0.0001
Loss index (Arithmetic)
Stent 0.18 0.73‡ 0.70 0.46 0.0001
Ribbon 0.26 0.12 0.58 0.15 0.0001
Lesion (ribbonmargin) 0.29 0.70 0.60 0.92 0.0468
Restenosis rate (%)
Stent 12 (20.3)* 32 (57.1) 0.001
Ribbon 13 (22.4) 33 (60.0) 0.001
Lesion (ribbonmargin) 14 (23.7) 34 (60.7) 0.001
Stent margin only 2 (3.4) 2 (3.4) NS
Ribbon margin only 1 (1.7) 1 (1.7) NS
Irradiated stent margin 1 (1.7) 1 (1.7) NS
*p 0.0832 for comparison of stent versus ribbon; †p 0.001 for comparison of stent
versus ribbon and stent versus ribbonmargin; ‡p  0.223 for comparison of stent
versus ribbonmargin.
Figure 2. Frequency of minimal lumen diameters (MLDs) at follow-up demonstrating a bimodal distribution of the iridium and placebo groups using the
stent MLD compared to a near-normal distribution of the iridium and placebo groups using the ribbonmargin MLD.
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Figure 3. Probability of recurrent restenosis according to the initial lesion length. Restenoses within the stent (A), the stent edges (B) and the entire treated
segment (ribbonmargins, C) are analyzed separately.
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edges depending on treatment allocation. Stent edge reste-
nosis is generally low, and it appears to be more frequent in
shorter lesions treated with radiation, and in longer lesions
treated with placebo. For any given lesion length, restenosis
within the stent and within the entire treated segment is
lower with radiation than with placebo and is increasing
with increasing initial lesion length in both groups.
Angiographic correlates of target lesion revascularization.
The follow-up percent DS obtained from the three angio-
graphic analyses, including the stent, the ribbon and the
ribbonmargin segments, correlated with clinically driven
target lesion revascularization (Fig. 4). Although no signif-
icant differences were found among the tested angiographic
variables, the one with the highest combined sensitivity and
specificity for predicting clinically driven TVR was the
binary restenosis rate (50% DS) obtained from the
ribbonmargin analysis segment (ROC area  0.806, p 
0.001), compared to the ribbon analysis segment (ROC area
0.804 0.130, p 0.001) or the stent analysis (ROC area
0.774  0.121, p  0.001).
DISCUSSION
Important differences exist in the early and late angiographic
findings after treatment of in-stent restenosis with gamma
radiation in WRIST, depending on whether the angio-
graphic measurements were made within the stent, irradi-
ated or irradiatedmargin segments. The greatest angio-
graphic benefit from 192Ir was obtained within the stent
segment, as evident by the lower restenosis rate and the
lower loss index compared to the other two segments
encompassing the irradiated segment, including the mar-
gins. Both stent edge restenosis and ribbon edge restenosis
were infrequent after gamma radiation, and no different
than with placebo; thus iridium therapy had no apparent
proliferative edge effect. In addition to the reduction in
restenosis, 192Ir also resulted in a more focal pattern of
restenosis among treatment failure. Despite the low fre-
quency of edge restenosis after gamma radiation in WRIST,
the angiographic analysis encompassing the irradiatedmargin
segment was the strongest correlate of TVR. These findings
underscore the importance of systematically including the
angiographic outcome of the radiation ribbon and its
margins in the angiographic analysis of brachytherapy trials.
Restenosis and the “edge effect” after 192Ir brachytherapy.
In the SCRIPPS trial (5,6), treatment of patients with 192Ir
reduced the angiographic restenosis within the stent by 79%
(8.3% vs. 39.3%; p  0.010) and at the margin of the stent
by 42% (8.3% vs. 14.3%, p  0.503). In WRIST, the
greatest reduction in restenosis was also within the stent
(20.3% vs. 57.1%, p  0.001), while both stent margin
restenosis (3.4%) and ribbon margin restenosis (1.7%) were
trivial and the same for 192Ir and placebo patients.
Sensitivity Specificity Area  SE p Value
Follow-up stent % DS 50% 64.29% 89.19% 0.774  0.121  0.001
Follow-up ribbon % DS 50% 66.07% 87.84% 0.804  0.130  0.001
Follow-up ribbonmargin% DS 50% 67.86% 86.49% 0.806  0.130  0.001
Figure 4. Receiver operator curves of the follow-up percent diameter stenosis (DS) for the stent, ribbon, and ribbonmargin analyses to determine the best
surrogate of target vessel revascularization. A follow-up 50% DS obtained from the ribbon or the ribbonmargin analyses had the highest combined
sensitivity and specificity for target lesion revascularization. FU  follow-up; ROC  receiver operator curve.
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The frequency distribution of the follow-up MLD based
on the ribbonmargin analysis further supports the absence
of a significant “edge effect” after gamma radiation in the
WRIST trial, because the follow-up MLD values were
systematically larger with 192Ir therapy compared to placebo
(Fig. 2). In addition, the longer length of radiation delivery
seeds used to cover the stent margins in this study (mean
radiation seed length over lesion length ratio 1.8) had no
apparent detrimental effects on the adjacent nonstented
arterial segments at six months.
Pattern of in-stent restenosis after 192Ir brachytherapy.
Consistent with the previous SCRIPPS trial (5), 192Ir
therapy in WRIST was the strongest protective predictor of
binary restenosis. Furthermore, when recurrent restenosis
occurred, angiographic lesions were significantly shorter
(more frequently focal) after 192Ir therapy compared to
placebo. Thus, in cases of treatment failure, 192Ir appears to
alter the pattern of in-stent restenosis, with an increase of
focal patterns (7). Because the angiographic pattern of
in-stent restenosis is the predominant predictor of long-
term clinical outcome (7), this observation may be of clinical
importance. Not only does 192Ir therapy produce fewer
failures than placebo, but radiation failures (more frequently
focal pattern) may have better prognosis than placebo
failures (more frequently diffuse pattern).
Among patients assigned to 192Ir therapy, similar high-
risk lesion and procedural characteristics as seen in non-
brachytherapy trials were predictive of restenosis, including
lesion length, ostial lesions, and LAD location.
Angiographic and clinical restenosis in vascular brachy-
therapy trials. Binary restenosis has been used as a surro-
gate of TVR in assessing the effectiveness of new devices in
interventional cardiology. In the WRIST study, despite the
low frequency of edge restenosis, the best predictor of TVR
was the binary restenosis rate obtained from the
ribbonmargin and the ribbon analysis (Fig. 4). This may
be due to the apparent shift in follow-up MLD away from
the original lesion site (evidenced by the follow-up MLD
being smaller within the ribbonmargin than within the
stent segment) in 192Ir-treated patients, a phenomenon
previously reported elsewhere (8). Therefore, selecting an
adequate length of analysis in the angiographic assessment
of vascular brachytherapy trials is particularly relevant the
greater the concern or frequency of edge restenosis. A
comprehensive segment of analysis that encompasses any
zone of injury, the radiation delivery device, and its dose
fall-off zones is necessary in the surrogate evaluation of this
new therapeutic modality.
Study limitations. First, despite using side branches and
other anatomic landmarks, the relative radiolucency of some
stents make precise localization of the stent within the artery
somewhat problematic for angiographic analysis, as well as
for precise positioning of 192Ir seeds within the stent at the
time of intervention. Second, although the injured area was
an integral part of the ribbonmargin analysis, the zones of
injury were not independently assessed in the present study,
which may have provided further insight into another
potential cause of vascular brachytherapy failure. Finally, a
systematic analysis of the dose fall-off zones to more
precisely quantify the “edge effect” in all patients was not
performed.
Conclusions. The efficacy of 192Ir therapy appears to
extend beyond the overall reduction in restenosis, also
altering the pattern of treatment failures to a more focal
restenosis pattern, which may have a better prognosis than
the diffuse placebo failures. Based on the radiation prescrip-
tion techniques used in WRIST, a proliferative effect related
to dose fall-off at the edge of the source was not demon-
strated. Despite infrequent “edge” restenosis in WRIST, the
appropriate angiographic surrogate end point in this and
other vascular brachytherapy trials where “edge effect” is of
concern should assess the luminal changes of the full extent
of the arterial segment exposed to radiation inclusive of dose
fall-off margins.
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